Irene J. Virgolini

Irene Johanna Virgolini (born December 29, 1962 in Klagenfurt ) is an Austrian nuclear medicine doctor , full university professor for nuclear medicine and director of the University Clinic for Nuclear Medicine at the Medical University of Innsbruck .

Life

After graduating from the upper secondary school in Klagenfurt, Virgolini studied medicine at the University of Vienna from 1981 , where she received her Dr. med. univ. doctorate. During her studies at the Institute for Human Genetics, Section for Histopathology, University of Vienna, her scientific interest was awakened and in 1985 she was strengthened by a study visit to the Sackler Medical School, Hasharon Hospital, Tel Aviv University , Israel. As a result, her scientific work began in the field of atherosclerosis research , which she carried out from 1985 to 1991 at the Institute for Physiology, University of Vienna. In addition to her research activities, she completed her training as a specialist in internal medicine (nuclear medicine) at the Vienna University Clinic from 1987, where she first worked as an assistant doctor and later (until 2000) as a senior doctor.

Virgolini was appointed University Lecturer for Experimental Nuclear Medicine in 1992 with her work on functional liver scintigraphy and in 1995 with her work on oncological receptor scintigraphy as University Lecturer in Internal Medicine. This was followed by the establishment of a working group for experimental nuclear medicine at the University of Vienna. In 2000 Virgolini took over the management of the Institute for Nuclear Medicine at the Lainz Hospital in Vienna. In 2003 she was appointed director of the University Clinic for Nuclear Medicine at the Medical University of Innsbruck and a full university professor. Since then, the Innsbruck University Clinic for Nuclear Medicine has been expanded in terms of clinic, research and teaching.

In 2018, Virgolini was appointed President of the international WARMTH (World Association of Radiopharmaceutical and Molecular Therapy), whose goal is the global promotion of molecular radionuclide therapy. In May 2018 she was admitted to the University Council of the Medical University of Vienna.

research

Scientific focus

Virgolini's clinical research focuses on the development and preclinical validation of new radiopharmaceuticals for nuclear medicine diagnostics and therapy ("Theragnostics"). Several new nuclear medicine tracer methods ( positron emission tomography - PET and SPECT ) were clinically established under Virgolini .

Virgolini's research deals, among other things, with the patient-related "Quality of Life" in the context of individualized high-dose therapy.

Publications and lecturing

Virgolini's scientific work appeared in around 380 publications in specialist journals (total impact factor> 900, citation index> 4400, Hirsch index 34, based on " Web of Science "). Since 1988 Irene J. Virgolini has been invited to international congresses as well as to national and international universities and faculties to give lectures on the subject of "Molecular Imaging and Therapy" ("Theragnostics").

Publications (selection)

I. Virgolini, C. Decristoforo, A. Haug, S. Fanti, C. Uprimny: Current status of theranostics in prostate cancer. In: Eur J Nucl Med Mol Imaging. 45 (3), Mar 2018, pp. 471–495. doi: 10.1007 / s00259-017-3882-2 . Epub 2017 Dec 28. Review.
I. Virgolini: Greetings from the New President of the World Association of Radiopharmaceutical and Molecular Therapy. In: World J Nucl Med. 17 (2), Apr-Jun 2018, pp. 67-69. doi: 10.4103 / wjnm.WJNM_27_18 . No abstract available.
MF Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska, WJG Oyen, A. Chiti, F. Giammarile, A. Sundin, S. Fanti: Guideline for PET / CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. In: Eur J Nucl Med Mol Imaging. 44 (9), Aug 2017, pp. 1588-1601. doi: 10.1007 / s00259-017-3728-y . Epub 2017 May 25.
L. Scarpa, S. Buxbaum, D. Kendler, K. Fink, J. Bektic, L. Gruber, C. Decristoforo, C. Uprimny, P. Lukas, W. Horninger, I. Virgolini: The 68Ga / 177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. In: European Journal of Nuclear Medicine and Molecular Imaging. January 12, 2017. doi: 10.1007 / s00259-016-3609-9 .
C. Uprimny, AS Kroiss, C. Decristoforo, J. Fritz, E. von Guggenberg, D. Kendler, L. Scarpa, G. di Santo, LG Roig, J. Maffey-Steffan, W. Horninger, IJ Virgolini: 68Ga PSMA-11 PET / CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumor. In: European Journal of Nuclear Medicine and Molecular Imaging. January 31, 2017. doi: 10.1007 / s00259-017-3631-6 .
C. Uprimny, AS Kroiss, C. Decristoforo, J. Fritz, B. Warwitz, L. Scarpa, LG Roig, D. Kendler, E. von Guggenberg, J. Bektic, W. Horninger, IJ Virgolini: Early dynamic imaging in 68Ga- PSMA-11 PET / CT allows discrimination of urinary bladder activity and prostate cancer lesions. In: European Journal of Nuclear Medicine and Molecular Imaging. 29th November 2016.
I. Virgolini, M. Gabriel, A. Kroiss, E. von Guggenberg, R. Prommegger, B. Warwitz, B. Nilica, LG Roig, M. Rodrigues, C. Uprimny: Current knowledge on the sensitivity of the (68) Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumors. In: European Journal of Nuclear Medicine and Molecular Imaging. October 2016. doi: 10.1007 / s00259-016-3395-4 .

Patents

In 1997 Virgolini received a patent for a carrier substance for radionuclides for the diagnosis and / or destruction of tumor tissue (Vienna Patent Office) and in 1998 an EU patent for radiolabeled somatostatin receptor ligands for diagnosis and therapy .

Awards

Some of the approximately 30 national and international prizes and awards that Virgolini has received for her scientific work:

1992: Award of the International Union of Angiology , Paris
1992 and 1994: Jean Debiesse Award from the European Association of Nuclear Medicine (EANM), Lisbon / Düsseldorf
1996: Martin-Gülzow Award from the German Society for Digestive and Metabolic Diseases, Aachen
1996 and 2008: Editorial Board Award of the Journal of Nuclear Medicine , Denver / New Orleans
1997: Mac Foster Award from the European Society of Clinical Investigation
2008 and 2010: Alavi-Mandell Award from the Society of Nuclear Medicine (SNM), New Orleans / Salt Lake City
2012: EANM Springer Prize Best Basic Science Paper 2011 , Milan.
2018: Under the leadership of Christian Uprimny: 1st Rudolf Höfer Prize , Innsbruck

literature

The 50th Anniversary of Nuclear Medicine in Innsbruck. In: European Journal of Nuclear Medicine and Molecular Imaging. 38, Nov 2011, p. 2106.
Nuclear Medicine Innsbruck celebrates its 50th birthday. In: Glandula. Journal of the Neuroendocrine Tumors Network (NeT). 16, 2011, p. 20.

Web links

Individual evidence

↑ Head of the Week: Irene J. Virgolini. In: iPoint: News archive of the University of Innsbruck until 2015. University of Innsbruck, February 9, 2004, accessed on February 11, 2017 .
^ Eva Dichand new chairwoman of the University Council of MedUni Vienna. In: meduniwien.ac.at. May 14, 2018, accessed July 23, 2018 .

personal data
SURNAME	Virgolini, Irene J.
ALTERNATIVE NAMES	Virgolini, Irene Johanna (full name)
BRIEF DESCRIPTION	Austrian nuclear medicine doctor
DATE OF BIRTH	December 29, 1962
PLACE OF BIRTH	Klagenfurt

[1] Head of the Week: Irene J. Virgolini. In: iPoint: News archive of the University of Innsbruck until 2015. University of Innsbruck, February 9, 2004, accessed on February 11, 2017 .

[2] Eva Dichand new chairwoman of the University Council of MedUni Vienna. In: meduniwien.ac.at. May 14, 2018, accessed July 23, 2018 .